Aerie Pharmaceuticals Inc. (NASDAQ:AERI) shares saw unusually-high trading volume on Wednesday . Approximately 371,314 shares were traded during trading, a decline of 5% from the previous session’s volume of 392,883 shares.The stock last traded at $20.12 and had previously closed at $19.73.

AERI has been the subject of a number of research analyst reports. Zacks Investment Research downgraded Aerie Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, July 26th. Needham & Company LLC restated a “buy” rating and set a $45.00 price objective on shares of Aerie Pharmaceuticals in a report on Tuesday. Brean Capital restated a “buy” rating on shares of Aerie Pharmaceuticals in a report on Monday, May 16th. Cantor Fitzgerald started coverage on Aerie Pharmaceuticals in a report on Thursday, June 2nd. They set a “buy” rating and a $44.00 price objective for the company. Finally, Canaccord Genuity reiterated a “buy” rating on shares of Aerie Pharmaceuticals in a report on Tuesday, May 3rd. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Aerie Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $42.50.

The stock’s market capitalization is $531.06 million. The firm’s 50-day moving average price is $18.02 and its 200-day moving average price is $16.13.

Aerie Pharmaceuticals (NASDAQ:AERI) last posted its quarterly earnings data on Wednesday, August 3rd. The company reported ($0.72) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.02. Equities analysts predict that Aerie Pharmaceuticals Inc. will post ($2.74) earnings per share for the current year.

In related news, major shareholder Foresite Capital Fund Ii, L.P. acquired 250,000 shares of the company’s stock in a transaction dated Friday, July 22nd. The shares were bought at an average price of $17.50 per share, for a total transaction of $4,375,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.